<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064116</url>
  </required_header>
  <id_info>
    <org_study_id>LY9</org_study_id>
    <secondary_id>CAN-NCIC-LY9</secondary_id>
    <secondary_id>ROCHE-CAN-NCIC-LY9</secondary_id>
    <secondary_id>MINT-M39045</secondary_id>
    <secondary_id>CDR0000309053</secondary_id>
    <nct_id>NCT00064116</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Rituximab in Treating Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Randomized Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With a CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells
      and either kill them or deliver cancer-killing substances to them without harming normal
      cells. It is not yet known whether combination chemotherapy is more effective with or without
      rituximab in treating patients with non-Hodgkin's lymphoma.

      PURPOSE: This randomized phase III trial is studying four different combination chemotherapy
      regimens and rituximab to see how well they work compared to four different combination
      chemotherapy regimens alone in treating patients with non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the time to treatment failure in patients with CD20-positive diffuse large
           B-cell non-Hodgkin's lymphoma treated with CHOP (cyclophosphamide, doxorubicin,
           vincristine, and prednisone)-like chemotherapy with vs without rituximab.

        -  Compare the tumor control, progression rate, and complete remission rate in patients
           treated with these regimens.

        -  Compare the disease-free and overall survival rate of patients treated with these
           regimens.

        -  Compare the toxicity of these regimens in these patients.

      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified
      according to participating center, bulky disease (no vs yes), International Prognostic Index
      score (0 vs 1), and chemotherapy (CHOP vs CHOEP vs PMitCEBO vs MACOP-B). Patients are
      randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive 1 of the following chemotherapy regimens according to
           participating country:

             -  CHOP: Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on
                day 1 and oral prednisone or prednisolone on days 1-5. Treatment repeats every 21
                days for 6 courses in the absence of disease progression or unacceptable toxicity.

             -  CHOEP-21: Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV
                on day 1; etoposide IV on days 1-3; and oral prednisone on days 1-5. Treatment
                repeats every 21 days for 6 courses in the absence of disease progression or
                unacceptable toxicity.

             -  PMitCEBO: Patients receive mitoxantrone IV, cyclophosphamide IV, and etoposide IV
                on day 1; vincristine IV and bleomycin IV on day 8; and oral prednisolone daily
                during weeks 1-4 and every other day during week 5. Treatment repeats every 14 days
                for 6 courses in the absence of disease progression or unacceptable toxicity.

             -  MACOP-B: Patients receive cyclophosphamide IV and doxorubicin IV on days 1, 15, 29,
                43, 57, and 71; methotrexate IV and vincristine IV on days 8, 36, and 64; bleomycin
                IV and vincristine IV on days 22, 50, and 78; and oral or intramuscular prednisone
                on days 1-84. Treatment continues in the absence of disease progression or
                unacceptable toxicity.

        -  Arm II: Patients receive arm I regimens (according to participating country) and
           rituximab as follows:

             -  CHOP and rituximab: Patients receive CHOP as in arm I and rituximab IV on day 1.

             -  CHOEP-21 and rituximab: Patients receive CHOEP-21 as in arm I and rituximab IV on
                day 1.

             -  PMitCEBO and rituximab: Patients receive PMitCEBO as in arm I and rituximab IV on
                day 1 during courses 1 and 4; on day 8 during courses 2 and 5; and on day 1 at 1
                and 4 weeks after completion of the last course of PMitCEBO chemotherapy.

             -  MACOP-B and rituximab: Patients receive MACOP-B as in arm I and rituximab IV on
                days 1, 22, 43, 64, 85, and 106.

      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 820 patients will be accrued for this study within
      approximately 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment failure (TTF) at 3 years</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate after completion of treatment</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 3 years</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor control measured by TTF with non-tumor events censored at 3 years</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS) measured by TTF after an event during and directly after treatment at 3 years</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression rate determined by dividing the number of patients with disease progression by number of patients with evaluable outcome at 3 years</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression measured at 3 years</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity assessed by NCI CTC v2.0 after completion of treatment</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">824</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A: CHOP-21</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle: day 22 Total number of cycles 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: CHOP-21 + Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rituximab 375 mg/m² i.v. day 1* Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Rituximab 375 mg/m² i.v. day 1</description>
    <arm_group_label>Arm B: CHOP-21 + Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHOP regimen</intervention_name>
    <description>Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6</description>
    <arm_group_label>Arm A: CHOP-21</arm_group_label>
    <arm_group_label>Arm B: CHOP-21 + Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diffuse large B-cell non-Hodgkin's lymphoma according to REAL
             classification

               -  Diagnosed within the past 6 weeks

               -  CD20+ disease

               -  Ann Arbor stage II, III, or IV disease or stage I bulky disease

          -  International Prognostic Index (IPI) score of 0 or 1

               -  Score 0 defined by all of the following:

                    -  Stage I or II disease

                    -  ECOG performance status of 0 or 1

                    -  Lactic dehydrogenase (LDH) no greater than upper limit of normal (ULN)

               -  Score 1 defined by 1 of the following:

                    -  Stage I or II disease; ECOG performance status of 0 or 1; and LDH greater
                       than ULN

                    -  Stage I or II disease; ECOG performance status 2 or 3; and LDH no greater
                       than ULN

                    -  Stage III or IV disease; ECOG performance status 0 or 1; and LDH no greater
                       than ULN

          -  Previously untreated disease

          -  Mediastinal B-cell lymphoma allowed

          -  No secondary lymphoma after prior chemotherapy or radiotherapy for other malignancies

          -  No transformed lymphoma

          -  No primary CNS lymphoma

          -  No primary gastrointestinal (MALT) lymphoma

          -  No post-transplant lymphoproliferative disorder

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 60

        Performance status

          -  See Disease Characteristics

          -  ECOG 0-3

        Life expectancy

          -  At least 3 months

        Hematopoietic

          -  Not specified

        Hepatic

          -  Bilirubin no greater than 2.0 mg/dL*

          -  Transaminases no greater than 3 times normal*

          -  No active chronic hepatitis B or C infection NOTE: *Unless related to lymphoma

        Renal

          -  Creatinine no greater than 2 times normal* NOTE: *Unless related to lymphoma

        Cardiovascular

          -  No myocardial infarction within the past 6 months

          -  No uncompensated heart failure

          -  No dilatative cardiomyopathy

          -  No coronary heart disease with ST segment depression on ECG

          -  No severe uncompensated hypertension

        Pulmonary

          -  No chronic lung disease with hypoxemia

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No known allergic reactions against foreign proteins

          -  No other prior malignancy except basal cell skin cancer or carcinoma in situ of the
             cervix

          -  No concurrent disease that would preclude study treatment

          -  No active infections requiring systemic antibiotics or antiviral medications

          -  No severe uncompensated diabetes mellitus

          -  No clinical signs of cerebral dysfunction

          -  No severe psychiatric disease

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior murine antibodies

        Chemotherapy

          -  No other concurrent anticancer chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No concurrent response-adapted (slow response or unconfirmed complete response)
             radiotherapy

        Surgery

          -  Not specified

        Other

          -  No prior lymphoma-specific treatment

          -  More than 12 weeks since prior participation in another clinical trial

          -  No prior participation in this study

          -  No other concurrent study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Imrie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. H. Bliss Murphy Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>AIB 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand River Regional Cancer Centre</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute - General Division</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niagara Health System</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2R 7C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-The Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trillium Health Centre - West Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9C 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PEI Cancer Treatment Centre,Queen Elizabeth Hospital</name>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <zip>C1A 8T5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA-Hopital Du St-Sacrement</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E; MabThera International Trial (MInT) Group. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008 May;9(5):435-44. doi: 10.1016/S1470-2045(08)70078-0. Epub 2008 Apr 8.</citation>
    <PMID>18400558</PMID>
  </results_reference>
  <results_reference>
    <citation>Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379-91.</citation>
    <PMID>16648042</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

